CDR2 and Behcet disease: The immune-mediated group comprised of 25 cases (24.3% of 103) consisting of anti-Ri (ANNA2) (6,24%), anti-NMDAR (5,20%), neuropsychiatric lupus erythematosus (NPLE) (4,16%), demyelinating disease (3,12%), anti-Yo (PCA-1) (2,8%), neuro-Behcet’s disease (1,4%), anti-AMPAR (1,4%), anti-GABAR (1,4%), anti-VGKC (1,4%), and co-existence of anti-NMDAR with anti-Ri (1,4%).